Global Point-of-Care Diagnostics for Clostridium Infectious Diseases Market Size (2023 - 2030):

Global Point-of-Care Diagnostics for Clostridium Infectious Diseases Market is estimated to be worth USD 838.05 million in 2022 and is projected to reach a value of USD 1450.73 million by 2030, growing at a fast CAGR of 7.1% during the forecast period 2023-2030.

Clostridium is a rod-shaped, gram-positive bacteria, members of which are tracked down in soil, water, and the digestive systems of people and other animals. Dormant cells are profoundly impervious to heat, desiccation, and toxic synthetics and cleansers. The sizes of the species vary. Clostridium butyricum, a typical species, is 0.6 μm across and 3 to 7 μm long. Numerous clostridium species are significant infectious agents that affect humans and other animals. C. botulinum is the agent that causes botulism. Botulism can be caused by eating canned foods that haven't been properly sterilized and are now contaminated with the botulinum toxin or by getting an infection in a wound.

Point-of-care diagnostics, or simple point-of-care testing (POCT), typically means carrying out a test utilizing a gadget or test pack in the presence of the patient and without the need to send a sample to a diagnostic laboratory. POC diagnostics is faster than laboratory testing as it can be done anywhere and anytime. This test can be performed by any healthcare practitioner. It is cheaper than the majority of laboratory tests. In addition, POC diagnostics is the most beneficial type of testing in case of emergency situations. As a result of these features and advantages, the Global Point-of-Care Diagnostics for Clostridium Infectious Diseases Market is estimated to have a fast CAGR during the forecasted period.

Global Point-of-Care Diagnostics for Clostridium Infectious Diseases Market Drivers:

The rising incidence of clostridium infectious diseases is fueling the growth of the global point-of-care diagnostics for the clostridium infectious diseases market.

The prevalence and severity of clostridium infections, a global public health concern, have skyrocketed over the past three decades, contributing significantly to the market's expansion. There has been a significant shift in the epidemiology of clostridium infections that is disproportionately more prevalent in older patients. Previously thought to be a nosocomial infection caused by antibiotic exposure, clostridium infection now affects low-risk populations in the community. Therefore, this factor drives the demand for POC diagnostics for the clostridium infectious diseases market.

The increasing consumption of antibiotics is another factor contributing to the growth of the global point-of-care diagnostics for the Clostridium infectious diseases market.

The prolonged use of antibiotics has been the most common cause of Clostridium infections. This consumption alters the normal colon bacteria, allowing the clostridium bacteria to grow. Cephalosporins, clindamycin, and quinolones like ciprofloxacin and levofloxacin are the antibiotics that are more likely to cause clostridium infections. Clostridium infections are rising due to the increased use of these antibiotics and antimicrobials. Therefore, this factor also drives the demand for POC diagnostics for clostridium infectious diseases.

Global Point-of-Care Diagnostics for Clostridium Infectious Diseases Market Challenges:

The global point-of-care diagnostics for clostridium infectious diseases market is encountering challenges, primarily in terms of lack of awareness and scarcity of resources associated with diagnostic tests. There is a lack of awareness regarding clostridium infections and the importance of quick and accurate diagnosis. Moreover, there may be a scarcity of resources, such as healthcare infrastructure and trained personnel, to perform diagnostic tests, particularly in underdeveloped countries. Thus, these challenges inhibit the growth of the global POC diagnostics for the clostridium infectious diseases market.

Global Point-of-Care Diagnostics for Clostridium Infectious Diseases Market Opportunities:

Market expansion strategies present a lucrative opportunity in the global point-of-care diagnostics for the clostridium infectious diseases market. Given the rising demand for point-of-care diagnostics for clostridium infectious diseases due to the rising incidence of clostridium infectious diseases and the increasing consumption of antibiotics, major POC diagnostics for clostridium infectious diseases companies can stand to gain significantly from this opportunity by expanding their advanced POC diagnostic testing products to emerging markets, which can provide rapid and accurate results, in order to broaden their customer base and boost their overall revenue.

COVID-19 Impact on the Global Point-of-Care Diagnostics for Clostridium Infectious Diseases Market:

The outbreak of the COVID-19 pandemic substantially impacted the global point-of-care diagnostics for the Clostridium infectious diseases market. The implementation of strict lockdowns, traveling restrictions, and social distancing measures across several nations hindered many companies' manufacturing capacities and caused a shortage of skilled workforce. The pandemic caused disruptions in supply chains and distribution of goods and services, which highly affected the availability and accessibility of POC diagnostics for clostridium infectious diseases. Moreover, the shifted focus of healthcare infrastructure resources and personnel to COVID-19 testing and treatment further worsened the demand for POC diagnostics for clostridium infectious diseases. These factors negatively impacted the growth of the global point-of-care diagnostics for the Clostridium infectious diseases market. Despite these challenges, the global point-of-care diagnostics for clostridium infectious diseases market is projected to recover and grow in the coming years.

Global Point-of-Care Diagnostics for Clostridium Infectious Diseases Market Recent Developments:

• In October 2022, Seres Therapeutics, Inc., a leading microbiome platform therapeutics company, unveiled that the Biologics License Application (BLA) for the investigational oral microbiome therapeutic SER-109 for the prevention of recurrent C. difficile infection (CDI) has been accepted for review by the Food and Drug Administration (FDA) of the United States.
• In April 2022, Adiso Therapeutics, Inc., a clinical-stage biopharmaceutical company, unveiled that Phase 1b clinical trial evaluating ADS024, an orally administered single strain live biotherapeutic product (SS-LBP), for the prevention of C. difficile infection (CDI) recurrence has completed patient enrollment.
• In May 2021, Recursion Pharmaceuticals, Inc., a digital biology company, unveiled that the company has commenced investigational new drug (IND)-enabling studies for REC-163964. REC-163964 is a first-in-class toxin inhibitor for the potential prophylactic use in high-risk patients and prevention of recurrent clostridium difficile infections (CDI).

POINT-OF-CARE DIAGNOSTICS FOR CLOSTRIDIUM INFECTIOUS DISEASES MARKET REPORT COVERAGE:

Global Point-of-Care Diagnostics for Clostridium Infectious Diseases Market Segmentation:

Global Point-of-Care Diagnostics for Clostridium Infectious Diseases Market Segmentation: By Technology

• Molecular Diagnostics
• Immunoassays
• Others

In 2022, the immunoassays segment held the highest market share. The growth can be attributed to immunoassays being a simple, fast, and cost-effective method for detecting clostridium infectious diseases, with better sensitivity and specificity compared to molecular diagnostics. Immunoassays use the specific binding of an antigen and an antibody reaction, which produces a detectable signal. There are a variety of formats for immunoassays, including dipstick assays, fluorescent immunoassays, and lateral flow assays, among others.

Global Point-of-Care Diagnostics for Clostridium Infectious Diseases Market Segmentation: By Variant

• Clostridium Difficile
• Clostridium Perfringens
• Clostridium Botulinum
• Clostridium Tetani
• Clostridium Sordellii

In 2022, the Clostridium difficile segment held the highest market share. The growth can be attributed to Clostridium difficile being the most common hospital-acquired infection found in patients. Clostridium difficile infection results from the disruption of normal, healthy bacteria in the colon (large intestine), often as a result of antibiotics. Immunoassays and molecular diagnostics are commonly used to diagnose this infection. In addition, the rising incidence and severity of clostridium difficile infection further propel this segment's growth.

Global Point-of-Care Diagnostics for Clostridium Infectious Diseases Market Segmentation: By End User

• Clinics
• Hospitals
• Independent Laboratories

In 2022, the hospital segment held the largest market share and is anticipated to continue dominance. The growth can be attributed to hospitals being the most common medium for diagnosing and treating clostridium infectious diseases. Hospitals often consist of essential infrastructure and resources for conducting complex diagnostic tests, including immunoassays and molecular diagnostics.

Global Point-of-Care Diagnostics for Clostridium Infectious Diseases Market Segmentation: By Region

• North America
• Europe
• Asia-Pacific
• Rest of the World

The global point-of-care diagnostics market for clostridium infectious diseases was dominated by North America in 2022. The well-established healthcare infrastructure in North American nations, including the United States and Canada, the high incidence of clostridium infectious diseases, as well as the rising adoption of advanced POC diagnostics for the detection of these diseases, account for the growth. Additionally, the region is home to Abbott Laboratories, Cepheid, Quidel Corporation, Hologic Inc., and Alere Inc., all of which are significant market players in the global point-of-care diagnostics for the Clostridium infectious diseases market.

Europe is anticipated to be the fastest-growing region during the forecast period, owing to the rising incidence of clostridium infectious diseases and increasing focus on improving healthcare infrastructure in European countries, including France, Germany, and Switzerland.

Global Point-of-Care Diagnostics for Clostridium Infectious Diseases Market Key Players:

1. Abbott Laboratories (United States)
2. bioMérieux SA (France)
3. Cepheid (United States)
4. Quidel Corporation (United States)
5. F. Hoffmann-La Roche Ltd (Switzerland)
6. Hologic Inc. (United States)
7. Alere Inc. (United States)
8. Thermo Fisher Scientific Inc. (United States)
9. R-Biopharm AG (Germany)
10. Sysmex Corporation (Japan)